Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].
Hasler-Strub U, Mueller A, Li Q, Thuerlimann B, Ribi K, Gerber S, von Moos R, Fehr M, Rochlitz C, Zaman K, Aebi S, Hochstrasser A, Gick U, Baertschi D, Greuter S, Schreiber A, Caspar CB, Trojan A, Condorelli R, Ruhstaller T; Swiss Group for Clinical Cancer Research (SAKK). Hasler-Strub U, et al. J Geriatr Oncol. 2023 Jan;14(1):101372. doi: 10.1016/j.jgo.2022.09.001. Epub 2022 Sep 18. J Geriatr Oncol. 2023. PMID: 36127284 Free article. Clinical Trial.
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
Zaman K, Winterhalder R, Mamot C, Hasler-Strub U, Rochlitz C, Mueller A, Berset C, Wiliders H, Perey L, Rudolf CB, Hawle H, Rondeau S, Neven P. Zaman K, et al. Among authors: hasler strub u. Eur J Cancer. 2015 Jul;51(10):1212-20. doi: 10.1016/j.ejca.2015.03.016. Epub 2015 Apr 16. Eur J Cancer. 2015. PMID: 25892646 Clinical Trial.
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na KJ, Bärtschi D, Borner M, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R; Swiss Group for Clinical Cancer Research (SAKK). Rochlitz C, et al. Among authors: hasler strub u. BMC Cancer. 2016 Oct 10;16(1):780. doi: 10.1186/s12885-016-2823-y. BMC Cancer. 2016. PMID: 27724870 Free PMC article. Clinical Trial.
A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
Gennari A, Sun Z, Hasler-Strub U, Colleoni M, Kennedy MJ, Von Moos R, Cortés J, Vidal MJ, Hennessy B, Walshe J, Parraga KA, Ribi K, Bernhard J, Murillo SM, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan MM, Jerusalem G; International Breast Cancer Study Group, Cancer Trials Ireland and SOLTI Group. Gennari A, et al. Among authors: hasler strub u. Ann Oncol. 2018 Mar 1;29(3):661-668. doi: 10.1093/annonc/mdx772. Ann Oncol. 2018. PMID: 29228091 Free article. Clinical Trial.
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.
Mamot C, Wicki A, Hasler-Strub U, Riniker S, Li Q, Holer L, Bärtschi D, Zaman K, von Moos R, Dedes KJ, Boos LA, Novak U, Bodmer A, Ritschard R, Obermann EC, Tzankov A, Ackermann C, Membrez-Antonioli V, Zürrer-Härdi U, Caspar CB, Deuster S, Senn M, Winterhalder R, Rochlitz C. Mamot C, et al. Among authors: hasler strub u. Sci Rep. 2023 Mar 6;13(1):3705. doi: 10.1038/s41598-023-30950-z. Sci Rep. 2023. PMID: 36879012 Free PMC article. Clinical Trial.
[Breast cancer: screening, treatment and follow-up].
Hasler-Strub U, Moos Rv. Hasler-Strub U, et al. Praxis (Bern 1994). 2010 Mar 31;99(7):413-8. doi: 10.1024/1661-8157/a000086. Praxis (Bern 1994). 2010. PMID: 20358516 Review. German.